Metsera, Inc./$MTSR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Metsera, Inc.
Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.
Ticker
$MTSR
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
96
ISIN
US59267L1070
Website
Metsera, Inc. Metrics
BasicAdvanced
$4.7B
-
-$8.99
-
-
Price and volume
Market cap
$4.7B
52-week high
$46.43
52-week low
$12.30
Average daily volume
976K
Financial strength
Current ratio
6.554
Quick ratio
6.484
Long term debt to equity
0.102
Total debt to equity
1.925
Interest coverage (TTM)
-550.04%
Profitability
EBITDA (TTM)
-178.196
Effective tax rate (TTM)
3.29%
Management effectiveness
Valuation
Price to book
9.19
Price to tangible book (TTM)
11.27
Price to free cash flow (TTM)
-9.447
Free cash flow yield (TTM)
-10.58%
Free cash flow per share (TTM)
-468.91%
Growth
Bulls say / Bears say
Metsera's IPO raised approximately $316 million, providing substantial capital to advance its obesity drug pipeline. (stocktitan.net)
Analysts have set a consensus price target of $55.25 for MTSR, indicating an 87.61% upside potential. (stockanalysis.com)
Metsera's MET-233i demonstrated 11.3% weight loss in a Phase 2a trial, showcasing promising efficacy in obesity treatment. (stocktitan.net)
Metsera reported a net loss of $209.1 million for the year ended December 31, 2024, reflecting significant financial challenges. (stocktitan.net)
The biotechnology sector is highly competitive, and Metsera's success depends on the clinical and commercial success of its pipeline, which is not guaranteed. (stocktitan.net)
Metsera's stock price has experienced volatility, with a 52-week range between $12.30 and $37.99, indicating potential instability. (defenseworld.net)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
Metsera, Inc. News
AllArticlesVideos
Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewsWire·1 month ago
Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data
Benzinga·1 month ago
Metsera rises as experimental weight-loss drug shows promise in small early-stage trial
Reuters·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Metsera, Inc. stock?
Metsera, Inc. (MTSR) has a market cap of $4.7B as of July 19, 2025.
What is the P/E ratio for Metsera, Inc. stock?
The price to earnings (P/E) ratio for Metsera, Inc. (MTSR) stock is 0 as of July 19, 2025.
Does Metsera, Inc. stock pay dividends?
No, Metsera, Inc. (MTSR) stock does not pay dividends to its shareholders as of July 19, 2025.
When is the next Metsera, Inc. dividend payment date?
Metsera, Inc. (MTSR) stock does not pay dividends to its shareholders.
What is the beta indicator for Metsera, Inc.?
Metsera, Inc. (MTSR) does not currently have a Beta indicator.